 Rothberg resigned as chief executive of CuraGen in 2005.CellDex Therapeutics acquired CuraGen in 2009 for $93.5 million in stock and reduced it to only five employees by October.In 2000, 454 Life Sciences was founded as a subsidiary of CuraGen; Rothberg was the CEO of CuraGen at the time.